Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade
Open accessThe DOI matches its Crossref record; 80 of the 82 references it cites were found in a registry or an index.
Abstract
Checkpoint blockade immunotherapy targeting the PD-1/PD-L1 inhibitory axis has produced remarkable results in the treatment of several types of cancer. Whereas cytotoxic T cells are known to provide important antitumor effects during checkpoint blockade, certain cancers with low MHC expression are responsive to therapy, suggesting that other immune cell types may also play a role. Here, we employed several mouse models of cancer to investigate the effect of PD-1/PD-L1 blockade on NK cells, a population of cytotoxic innate lymphocytes that also mediate antitumor immunity. We discovered that PD-1 and PD-L1 blockade elicited a strong NK cell response that was indispensable for the full therapeutic effect of immunotherapy. PD-1 was expressed on NK cells within transplantable, spontaneous, and genetically induced mouse tumor models, and PD-L1 expression in cancer cells resulted in reduced NK cell responses and generation of more aggressive tumors in vivo. PD-1 expression was more abundant on NK cells with an activated and more responsive phenotype and did not mark NK cells with an exhausted phenotype. These results demonstrate the importance of the PD-1/PD-L1 axis in inhibiting NK cell responses in vivo and reveal that NK cells, in addition to T cells, mediate the effect of PD-1/PD-L1 blockade immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“PD-1 (a.k.a. CD279) is expressed on activated T cells as well as other cells including but not limited to B cells, natural killer (NK) cells, and myeloid cells (Hsu et al., 2018; Nam et al., 2019).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Hsu et al., 2018
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Kohrt, H. E., Houot, R., Weiskopf, K., Goldstein, M. J., Scheeren, F., Czerwinski, D., Colevas, A. D., Weng, W.-K., Clarke, M. F., Carlson, R. W., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci61226 · Cited by 226
RetractedPD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Ansell, S. M., Lesokhin, A. M., Borrello, I., Halwani, A., Scott, E. C., Gutierrez, M., Schuster, S. J., Millenson, M. M., Cattry, D., Freeman, G. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411087 · Cited by 3,560
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., Daud, A., Hodi, F. S., Hwu, W.-J., Kefford, R., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,392
Cited by
Items 301–400 of 848
Hu, Y., Cai, Z., Huang, R., Wang, D., Ju, H., & Chen, D. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02192-8 · Cited by 33
“The blockade of PD-1 and PD-L1 elicited a strong NK cell response, indicating that NK cells were indispensable for the full therapeutic effect of immunotherapy [18].”
NK Cell-Fc Receptors Advance Tumor Immunotherapy
Sanseviero, E. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8101667 · Cited by 34
“Indeed, NK cells have been shown to contribute to the efficacy of anti-PD-1/PD-L1 treatment through reinvigoration of NK cell effector functions [63].”
BackgroundProgesterone promotes immunomodulation and tumor development in the murine mammary gland
Werner, L. R., Gibson, K. A., Goodman, M. L., Helm, D. E., Walter, K. R., Holloran, S. M., Trinca, G. M., Hastings, R. C., Yang, H. H., Hu, Y., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001710 · Cited by 38
Wen, X., Xu, Z., Jin, Y., Xia, P., Ma, J., Qian, W., Lin, J., & Qian, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.717527 · Cited by 38
“(45) proposed that blocking PD-1/PD-L1 may activate NK cells that were indispensable for the treatment effect of these therapies.”
BackgroundBurgeoning Exploration of the Role of Natural Killer Cells in Anti-PD-1/PD-L1 Therapy
Bai, R., & Cui, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.886931 · Cited by 35
“Several murine tumor models have shown that PD-1 NK cells present at the site of PD-L1 tumors exhibit an exhaustive phenotype and that PD-1/PD-L1 interaction strongly inhibits NK cell-mediated antitumor immunity (32).”
BackgroundInfluentialChiba, M., Shimono, J., Ishio, T., Takei, N., Kasahara, K., Ogasawara, R., Ara, T., Goto, H., Izumiyama, K., Otsuguro, S., et al. (2022) · Blood · doi:10.1182/blood.2022015646 · Cited by 35
Engaging natural killer cells for cancer therapy via NKG2D, CD16A and other receptors
Whalen, K. A., Rakhra, K., Mehta, N. K., Steinle, A., Michaelson, J. S., & Baeuerle, P. A. (2023) · mAbs · doi:10.1080/19420862.2023.2208697 · Cited by 34
“Preclinical data have demonstrated the importance of this pathway in suppressing NK cell activity and may contribute to the activity of anti-PD-1/PD-L1 mAb therapies in the clinic.(42,48) In summary, NK cell activity is kept in a delicate balance and tightly controlled by a network of multiple regulatory proteins.”
BackgroundMaintaining the Balance: Regulation of NK Cell Activity
Imširović, V., Wensveen, F. M., Polić, B., & Jelenčić, V. (2024) · Cells · doi:10.3390/cells13171464 · Cited by 34
“The most successful immunotherapy, anti-PD-1/PD-1L treatment, stimulates both T cell and NK cell responses [95,96].”
BackgroundCAR-NK cells for gastrointestinal cancer immunotherapy: from bench to bedside
Zhu, X., Xue, J., Jiang, H., & Xue, D. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02151-3 · Cited by 33
“Blocking these check-points can significantly enhance NK cell functions [167, 168].”
BackgroundGhosh, S., Dutta, R. K., Goswami, D., Ghatak, D., & De, R. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189471 · Cited by 38
Huang, T.-Y., Chang, T., Chin, Y., Pan, Y.-S., Chang, W.-J., Liu, F., Hastuti, E. D., Chiu, S.-J., Wang, S.-H., Changou, C. A., et al. (2020) · Cells · doi:10.3390/cells9081830 · Cited by 35
“The PD-1/PD-L1 axis can modulate nature killer cells’ actions on tumor cells [44,45].”
BackgroundKilling the Invaders: NK Cell Impact in Tumors and Anti-Tumor Therapy
Molgora, M., Cortez, V. S., & Colonna, M. (2021) · Cancers · doi:10.3390/cancers13040595 · Cited by 33
Recruited and Tissue-Resident Natural Killer Cells in the Lung During Infection and Cancer
Franklin, M., Connolly, E., & Hussell, T. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.887503 · Cited by 35
Davis-Marcisak, E. F., Fitzgerald, A. A., Kessler, M. D., Danilova, L., Jaffee, E. M., Zaidi, N., Weiner, L. M., & Fertig, E. J. (2021) · Genome Medicine · doi:10.1186/s13073-021-00944-5 · Cited by 34
Wang, Y., JIN, J., Li, Y., Zhou, Q., YAO, R., Wu, Z., Hu, H., Fang, Z., Dong, S., Cai, Q., et al. (2021) · Translational research · doi:10.1016/j.trsl.2021.10.006 · Cited by 32
Dinavahi, S. S., Chen, Y., Punnath, K., Berg, A. S., Herlyn, M., Foroutan, M., Huntington, N. D., & Robertson, G. P. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0587 · Cited by 33
Yu, D., Yang, P., Lu, X., Huang, S., Liu, L., & Fan, X. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-023-01184-3 · Cited by 34
“[77] proposed that NK cells would mediate the effect of PD-1/PD-L1 antibody therapy along with T cells.”
BackgroundProgress of research on PD-1/PD-L1 in leukemia
Cao, H., Wu, T., Zhou, X., Xie, S., Sun, H., Sun, Y., & Li, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1265299 · Cited by 32
“NK cells can obtain PD-1 from leukemia cells by endocytosis in tumor cells, and PD-L1 in tumor cells interacts with PD-1 of NK cells to reduce NK cell responses and produce more aggressive tumors (38 – 40) (Figure 1).”
BackgroundMoinuddin, A., Poznanski, S. M., Portillo, A. L., Monteiro, J. K., & Ashkar, A. A. (2024) · Immunological Reviews · doi:10.1111/imr.13316 · Cited by 34
“157 Benci et al 158 also demonstrated that aside from tumor cells, various CD45 + immune cells (macrophages, dendritic cells, CD4 + T cells, and CD8 + cells) also increase PD-L1 expression following IFN-γ treat-ment.”
BackgroundIDO Targeting in Sarcoma: Biological and Clinical Implications
Nafia, I., Toulmonde, M., Bortolotto, D., Chaïbi, A., Bodet, D., Rey, C., Velasco, V., Larmonier, C. B., Cerf, L., Adam, J., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00274 · Cited by 32
“Evidences from the literature support the implication of NK cells in the antitumor activity of PD1/PDL1 blockers (25).”
BackgroundZhao, J., Yang, Z., Tu, M., Meng, W., Gao, H., Li, M. D., & Li, L. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.608641 · Cited by 34
“Recently, high infiltration of immune cells, such as natural killer (NK) cells and CD8 and CD4 T effector cells, was reported to be associated with a response to clinical anti-PD1/PD-L1-based therapy (14, 15).”
BackgroundXie, X., Tang, Y., Sheng, J., Shu, P., Zhu, X., Cai, X., Zhao, C., Wang, L., & Huang, X. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.761758 · Cited by 32
Tumor intrinsic and extrinsic functions of CD73 and the adenosine pathway in lung cancer
Kowash, R., & Akbay, E. A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1130358 · Cited by 31
Radiation therapy and the innate immune response: Clinical implications for immunotherapy approaches
Gómez, V., Mustapha, R., Ng, K., & Ng, T. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14351 · Cited by 32
Yang, Y., Wang, C., Sun, H., Jiang, Z., Zhang, Y. X., & Pan, Z. (2020) · Cancer Gene Therapy · doi:10.1038/s41417-020-0186-7 · Cited by 30
NK Cells in a Tug-of-War With Cancer: The Roles of Transcription Factors and Cytoskeleton
Lee, E. H. C., Wong, D. C. P., & Ding, J. L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.734551 · Cited by 31
Wenthe, J., Naseri, S., Hellström, A.-C., Moreno, R., Ullenhag, G. J., Alemany, R., Lövgren, T., Eriksson, E., & Loskog, A. (2022) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2022.01.003 · Cited by 30
“PD-1+ NK cells have been demonstrated to be highly functional, but can be impaired by PD-L1 engagement, and are involved in the therapeutic effect of PD-L1 blockade.(31,32)”
Westhaver, L. P., Nersesian, S., Nelson, A., MacLean, L. K., Carter, E. B., Rowter, D., Wang, J., Gala-López, B., Stadnyk, A. W., Johnston, B., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110847 · Cited by 32
Natural killer cells: the next wave in cancer immunotherapy
Chen, X., Jiang, L., & Liu, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.954804 · Cited by 33
Tang, M. M., Sun, Y., Huang, C., Chen, L., Liu, B., You, B., Wang, Z., & Chang, C. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04956-w · Cited by 31
“A high dose DHT/AR suppresses NK cells immunotherapy efficacy to kill CRPC cells via up-regulating PD-L1 expression in CRPC cells It was reported that PD-L1 expression in cancer cells could lead to reduced NK cell responses via altering the PD-1/PD-L1 inhibitory axis [19].”
BackgroundMethodInfluentialReprogramming natural killer cells for cancer therapy
Wang, K., Wang, L., Wang, Y., Xiao, L., Wei, J., Hu, Y., Wang, D., & Huang, H. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.01.027 · Cited by 30
Guo, S., Huang, C., Han, F., Chen, B., Ding, Y., Zhao, Y., Chen, Z., Wen, S., Wang, M., Shen, B., et al. (2021) · Stem Cells International · doi:10.1155/2021/9989790 · Cited by 28
“Immunotherapy targeting the PD1/PD-L1 inhibitory axis elicited long-term remission in a broad spectrum of cancers [11].”
BackgroundUnleashing the power of NK cells in anticancer immunotherapy
Vogler, M., Shanmugalingam, S., Särchen, V., Reindl, L. M., Grèze, V., Buchinger, L., Kühn, M. W. M., & Ullrich, E. (2021) · Journal of Molecular Medicine · doi:10.1007/s00109-021-02120-z · Cited by 31
Kim, E. J., Cho, Y., Kim, D. H., Ko, D., Do, E., Kim, S., Kim, Y. M., Jung, J. S., Kang, Y., Ji, W., et al. (2021) · Cancer Research and Treatment · doi:10.4143/crt.2021.986 · Cited by 28
“process of PD-1/PD-L1 axis blockade, as shown by our xenograft tumors which derived from NSCLC cells depleting T cells, NK cells, and both cells, respectively (S1 Fig), consistent with previous study [16], indicating that NK cells may play roles in helping to recruit a T cell response and/or by killing tumor cells dir…”
BackgroundResultInfluentialWang, Y.-M., Qiu, J.-J., Qu, X.-Y., Peng, J., Lu, C., Zhang, M., Zhang, M.-X., Qi, X.-L., Lv, B., Guo, J.-J., et al. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2034257 · Cited by 31
Harnessing Natural Killer Cells for Lung Cancer Therapy
Ma, S., Caligiuri, M. A., & Yu, J. (2023) · Cancer Research · doi:10.1158/0008-5472.can-23-1097 · Cited by 28
ILC regulation of T cell responses in inflammatory diseases and cancer
Warner, K., & Ohashi, P. S. (2019) · Seminars in Immunology · doi:10.1016/j.smim.2019.101284 · Cited by 29
Kravtsova‐Ivantsiv, Y., Goldhirsh, G., Ivantsiv, A., Itzhak, O. B., Kwon, Y. T., Pikarsky, E., & Ciechanover, A. J. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2019604117 · Cited by 28
“Recently, it was shown that PD-1 and PD-L1 blockade elicited a strong natural killer (NK) cell antitumoral activity (32).”
BackgroundZhang, D., Zheng, Y., Lin, Z., Liu, X., Li, J., Yang, H., & Tan, W. (2020) · Angewandte Chemie · doi:10.1002/ange.202002145 · Cited by 28
Immune Evasion of Hepatoma Cancer Stem-Like Cells from Natural Killer Cells
Kimura, Y., Tsunedomi, R., Yoshimura, K., Matsukuma, S., Shindo, Y., Matsui, H., Tokumitsu, Y., Yoshida, S., Iida, M., Suzuki, N., et al. (2022) · Annals of Surgical Oncology · doi:10.1245/s10434-022-12220-w · Cited by 27
Expression, regulation, and function of PD-L1 on non-tumor cells in the tumor microenvironment
Hu, L., Sun, C., Yuan, K., & Yang, P. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.104181 · Cited by 30
Effect of Extracellular Vesicles Derived From Tumor Cells on Immune Evasion
Liu, X., To, K. K. W., Zeng, Q., & Fu, L. (2025) · Advanced Science · doi:10.1002/advs.202417357 · Cited by 32
Feng, Y., Hu, Y., Liu, J., Zhang, X., Zhang, Y., Wang, Z., & Pu, K. (2025) · Angewandte Chemie International Edition · doi:10.1002/anie.202507765 · Cited by 27
Vitiello, P. P., Rousseau, B., Chilà, R., Battuello, P., Amodio, V., Battaglieri, V., Grasso, G., Scardellato, S., Anselmo, A., Clemente, F., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.05.014 · Cited by 27
Dysfunction of natural killer cells promotes immune escape and disease progression in endometriosis
Jiang, W., Xu, W., & Chen, F. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1657605 · Cited by 28
“The programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) checkpoint axis is a prominent focus in NK cell – based immunotherapy (58).”
Tang, Y., Xu, Q., Hu, L., Yan, X., Feng, X., Yokota, A., Wang, W., Zhan, D., Krishnamurthy, D., Ochayon, D. E., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0833 · Cited by 28
Downregulation of NKG2DLs by TGF-β in human lung cancer cells
Lee, Y. S., Choi, H., Cho, H.-R., Son, W.-C., Park, Y.-S., Kang, C., & Bae, J. (2021) · BMC Immunology · doi:10.1186/s12865-021-00434-8 · Cited by 27
Effects of exercise and anti-PD-1 on the tumour microenvironment
Buss, L. A., Williams, T., Hock, B. D., Ang, A. D., Robinson, B. A., Currie, M. J., & Dachs, G. U. (2021) · Immunology Letters · doi:10.1016/j.imlet.2021.08.005 · Cited by 30
Anti–PD-1 Checkpoint Therapy Can Promote the Function and Survival of Regulatory T Cells
Vick, S. C., Kolupaev, O., Perou, C. M., & Serody, J. S. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2001334 · Cited by 29
Gastric cancer mesenchymal stem cells inhibit natural killer cell function by up-regulating FBP1
Han, F., Guo, S., Huang, C., Cui, L., Zhao, Y., Ma, J., Zhu, M., Chen, Z., Wang, M., Shen, B., et al. (2021) · Central European Journal of Immunology · doi:10.5114/ceji.2021.111753 · Cited by 28
“Among effector cells, NK cells are innate lymphocytes with cytotoxic activity against cancer cells and microbial infection by releasing cytokines and chemokines [4] and have shown great potential for immunotherapy [5].”
BackgroundWang, T., Denman, D., Bacot, S. M., & Feldman, G. M. (2022) · Biomedicines · doi:10.3390/biomedicines10051181 · Cited by 28
Yang, L., Hong, X., Gilbertsen, A. J., Smith, K. A., Racila, E. V., Bitterman, P. B., & Henke, C. A. (2023) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00028.2023 · Cited by 29
In situ vaccination caused by diverse irradiation-driven cell death programs
Wang, Y., Li, Y., Yang, Y., Swift, M. L., Zhang, Z., Wu, S., Sun, Y., & Yang, K. (2024) · Theranostics · doi:10.7150/thno.86004 · Cited by 29
“While NK cell-based immunothe-rapies are under intensive research, the precise role of NK cells within the confluence of combined radiotherapy-immunotherapy remains ambiguous [214].”
BackgroundTargeting phagocytosis checkpoints for cancer immunotherapy
Veillette, A., Li, J., Galindo, C. C., Davidson, D., & Tang, Z.-H. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-025-00893-w · Cited by 32
“In addition to activated T cells, PD-1 is expressed on B cells, NK cells and dendritic cells 171–173 .”
Immune checkpoints in hematologic malignancies: What made the immune cells and clinicians exhausted!
Hajifathali, A., Parkhideh, S., Kazemi, M. H., Chegeni, R., Roshandel, E., & Gholizadeh, M. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.29769 · Cited by 26
Morschhauser, F., Ghosh, N., Lossos, I. S., Palomba, M. L., Mehta, A., Casasnovas, O., Stevens, D. A., Katakam, S. B., Knapp, A., Nielsen, T. G., et al. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00539-8 · Cited by 27
Jovanovic, M. Z., Geller, D., Gajović, N., Jurišević, M., Arsenijević, N., Jovanović, M. M., Šupić, G., Vojvodic, D., & Jovanovic, I. (2021) · Life Science · doi:10.1016/j.lfs.2021.120214 · Cited by 24
Yang, G., Zheng, B., Yu, Y., Huang, J., Zhu, H., Deng, D., & Li, J. (2022) · BioMed Research International · doi:10.1155/2022/7037497 · Cited by 26
RetractedThe Important Roles of Natural Killer Cells in Liver Fibrosis
Yang, M. J., Vanderwert, E., Kimchi, E. T., Staveley-O’Carroll, K. F., & Li, G. (2023) · Biomedicines · doi:10.3390/biomedicines11051391 · Cited by 28
Immune evasion and therapeutic opportunities based on natural killer cells
Zhang, J., Guo, F., Li, L., Zhang, S., & Wang, Y. (2023) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2023.03.07 · Cited by 28
Targeting PD-L1 in cholangiocarcinoma using nanovesicle-based immunotherapy
Gondaliya, P., Sayyed, A. A., Yan, I. K., Driscoll, J., Ziemer, A., & Patel, T. C. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.06.006 · Cited by 26
Knab, V. M., Gotthardt, D., Klein, K., Grausenburger, R., Heller, G., Menzl, I., Prinz, D., Trifinopoulos, J., List, J., Fux, D. A., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-04279-2 · Cited by 27
Maprotiline Prompts an Antitumour Effect by Inhibiting PD-L1 Expression in Mice with Melanoma
Liang, L., Li, Y., Jiao, Y., Zhang, C., Shao, M., Jiang, H., Wu, Z., Chen, H., Guo, J., Jia, H., et al. (2023) · Current Molecular Pharmacology · doi:10.2174/0118761429259562230925055749 · Cited by 25
Park, S. H., Lee, J. H., Yun, H. J., Kim, S.-H., & Lee, J. (2024) · Annals of Laboratory Medicine · doi:10.3343/alm.2023.0443 · Cited by 26
“Consistent with previous findings [8-10], PD-1 expression on the surfaces of tumor-infiltrating NK and CD8 + T cells was significantly upregulated compared with that on splenic naïve NK and CD8 + T cells (Supplemental Data Fig.”
BackgroundResultInfluentialCheng, Y., Han, X., Lai, X., & Wei, X. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.156093 · Cited by 25
The Role of Chemokines in Orchestrating the Immune Response to Pancreatic Ductal Adenocarcinoma
Lekan, A. A., & Weiner, L. M. (2024) · Cancers · doi:10.3390/cancers16030559 · Cited by 25
“Work by Fridlender et al., using a transcriptomic approach to analyze surface marker expression by neutrophils present in tumors of AB12 mesothelioma tumor-bearing mice, found that naïve neutrophil-and granulocytic-derived MDSCs (g-MDSCs) significantly overlap in terms of mRNA profiles [141].”
BackgroundChoi, M. G., Kim, Y. J., Lee, J. C., Rho, J. K., & Choi, C. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13677 · Cited by 28
Non-canonical PD-1 signaling in cancer and its potential implications in clinic
Zha, H., Jiang, Y., Wang, X., Shang, J., Wang, N., Yu, L., Zhao, W., Li, Z., Zhang, X., Zhang, X., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001230 · Cited by 25
Jacobs, B., Gebel, V., Heger, L., Grèze, V., Schild, H., Dudziak, D., & Ullrich, E. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.670540 · Cited by 26
Oh, S. J., Lee, H.-J., Song, K., Kim, S., Cho, E., Lee, J., Bosenberg, M., & Kim, T. W. (2022) · Journal of Clinical Investigation · doi:10.1172/jci147908 · Cited by 24
“1 P0 cells), which has been frequently used as a preclinical tumor model for study of cancer biology and tumor immunology as well as evaluating the efficacy of ICB therapy (36-39), by three rounds of in vivo selection following PD-1 blockade (Supplemental Figure 3).”
Cui, J., Jia, L., Chen, N., Chen, X., Niu, C., Liu, Z., Ma, K., Wang, N., Yang, L., Zhao, Y., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1074906 · Cited by 28
“Anti-PD-1 therapy could improve their responsiveness and tumor control even in the absence of T cell cells, indicating that, in addition to T cells, other immune cells, such as NK cells, could also mediate the effect of PD-1/PD-L1 blockade immunotherapy (3, 4).”
BackgroundChen, L., Liu, S. J., Adah, D., Sun, Q., Liang, Z., Ho, M., & Sun, B. (2023) · Immunology · doi:10.1111/imm.13624 · Cited by 27
Aru, B., Pehlivanoğlu, C., Dal, Z., DERELI-CALISKAN, N. N., Gürlü, E., & Demirel, G. Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1108200 · Cited by 26
Dumolard, L., Aspord, C., Marche, P. N., & Jílková, Z. M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1148111 · Cited by 28
Ye, Y., Qin, G., Yang, H., Hao, J., Zeng, Q., Zheng, D., Ye, S., Zhang, Z., Liu, T., Luo, K. Q., et al. (2024) · Advanced Science · doi:10.1002/advs.202400888 · Cited by 27
Ruiz, M. G., Isla, D., Cruellas, M., Gálvez, E. M., Lastra, R. P., Ocáriz, M., Paño, J. R., Ramírez-Labrada, A., Sesma, A., Torres-Ramón, I., et al. (2020) · Cells · doi:10.3390/cells9061525 · Cited by 27
“On the one hand, NK cells supported T lymphocytes in the tumor response against tumors with high expression of MHC and self-antigens, and on the other hand, they became the main cytotoxic cells in those tumors with low expression of MHC even in PD-L1 negative tumors [41].”
BackgroundTargeting the SHP2 phosphatase promotes vascular damage and inhibition of tumor growth
Wang, Y., Salvucci, O., Ohnuki, H., Tran, A. D., Ha, T., Feng, J., DiPrima, M., Kwak, H., Wang, D., Yu, Y., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202114089 · Cited by 24
The Biological Role and Therapeutic Potential of NK Cells in Hematological and Solid Tumors
Velichinskii, R. A., Streltsova, M. A., Kust, S. A., Sapozhnikov, A. M., & Kovalenko, E. I. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111385 · Cited by 26
Zha, C., Yang, X., Yang, J., Zhang, Y., & Huang, R. (2024) · Annals of Hematology · doi:10.1007/s00277-024-06117-9 · Cited by 24
“These inhibitory receptors are also present on other anti-tumor cells, such as NK cells [94, 95] and macrophages [90].”
Chen, L., Li, B., Zu, M., Reis, R. L., Kundu, S. C., & Xiao, B. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.06.012 · Cited by 24
Natural killer cells in the brain tumor microenvironment: Defining a new era in neuro-oncology
Fares, J., Fares, M. Y., & Fares, Y. (2019) · Surgical Neurology International · doi:10.25259/sni-97-2019 · Cited by 24
“It has been shown that PD-1/PD-L1 blockade elicits a strong NK cell response that is indispensable for the full therapeutic effect of immunotherapy.[20] Ultimately, this can increase the portion of patients that can benefit from immunotherapy.”
BackgroundReticker-Flynn, N. E., & Engleman, E. G. (2020) · eLife · doi:10.7554/elife.53839 · Cited by 26
Masemann, D., Meissner, R., Schied, T., Lichty, B. D., Rapp, U. R., Wixler, V., & Ludwig, S. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1885778 · Cited by 25
“and TAMs is associated with suppressed cytotoxic NK and T cell responses and correlates with poor prognoses in NSCLCpatients.(20,21) Thus, we aimed to investigate the lung immune status of innate and adaptive cytotoxic immune cell”
BackgroundCao, C., Xu, Q., Zhu, Z., Xu, M., Ye, W., Lin, S., Sheng, C., Zhi, W., Hong, P., Huang, X., et al. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216809 · Cited by 23
NK cell based immunotherapy against oral squamous cell carcinoma
Zhang, Y., Xie, J., Wu, H., Huang, J., Zheng, D., Wang, S., Jia, X., He, Z., Gong, Y., Ju, L., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1440764 · Cited by 27
Mestiri, S., Sami, A., Sah, N., El-Ella, D. M. A., Khatoon, S., Shafique, K., Raza, A., Mathkor, D. M., & Haque, S. (2025) · Cancer and Metastasis Reviews · doi:10.1007/s10555-025-10244-8 · Cited by 28
“Consequently, the immunosuppressed phenotype and activity impairment of TME-infiltrated NK cells may contribute to the inefficacy of ICIs in NSCLC [79, 80].”
NK cells for PD-1/PD-L1 blockade immunotherapy: pinning down the NK cell
Dunai, C., & Murphy, W. J. (2018) · Journal of Clinical Investigation · doi:10.1172/jci123121 · Cited by 23
“This is particularly important, as the data by Hsu et al. clearly show a significant contribution by T cells following anti– PD-L1 treatment in some of the tumor models (19).”
MethodKasanen, H. H. E., Hernberg, M., Mäkelä, S., Brück, O. E., Juteau, S., Kohtamäki, L. M., Ilander, M. M., Mustjoki, S. M., & Kreutzman, A. S. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02497-9 · Cited by 24
Bacot, S. M., Harper, T. A., Matthews, R. L., Fennell, C. J., Akue, A. D., KuKuruga, M. A., Lee, S., Wang, T., & Feldman, G. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239023 · Cited by 25
“Third, recent studies indicate that the mechanism of anti-PD-1 therapy occurs not only through modulating T cell responses, but also potentially through modulating NK cell and macrophage functions [38,39].”
BackgroundLe, D. T., Huynh, T. R., Burt, B. M., Buren, G. V., Abeynaike, S. A., Zalfa, C., Nikzad, R., Kheradmand, F., Tyner, J. J., & Paust, S. (2021) · JCI Insight · doi:10.1172/jci.insight.140116 · Cited by 23
“Indeed, tumor-exhausted CTLs and NK cells express high levels of PD-1 receptor (39), and tumor cells escape immune attack through the expression of PD-ligands (40).”
Immune Checkpoints and Innate Lymphoid Cells—New Avenues for Cancer Immunotherapy
Jacquelot, N., Ghaedi, M., Warner, K., Chung, D. C., Crome, S. Q., & Ohashi, P. S. (2021) · Cancers · doi:10.3390/cancers13235967 · Cited by 23
Natural killer cell therapy: A new frontier for obesity-associated cancer
Mylod, E., Lysaght, J., & Conroy, M. J. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215620 · Cited by 22
CMTM6 and CMTM4 as two novel regulators of PD-L1 modulate the tumor microenvironment
Zhang, T., Yu, H., Dai, X., & Zhang, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.971428 · Cited by 27
New avenues for melanoma immunotherapy: Natural Killer cells?
Cristiani, C. M., Garofalo, C., Passacatini, L. C., & Carbone, E. (2019) · Scandinavian Journal of Immunology · doi:10.1111/sji.12861 · Cited by 23
Natoli, M., Bonito, N. A., Robinson, J. D., Ghaem‐Maghami, S., & Mao, Y. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02544-5 · Cited by 23
“In line with a recent study, this supports the indispensable and non-redundant role of NK cells in cancer immunotherapy [22] and could be employed to reveal functional effects of NK cell stimulating therapies such as anti-NKG2A mAb [23] or interleukin 15 [24].”
ResultVeinalde, R., Pidelaserra-Martí, G., Moulin, C., Jeworowski, L. M., Küther, L., Buchholz, C. J., Jäger, D., Ungerechts, G., & Engeland, C. E. (2021) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2021.11.020 · Cited by 23
Innate tumor killers in colorectal cancer
Zhong, F., Lin, Y., Jing, X., Ye, Y., Wang, S., & Shen, Z. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.12.022 · Cited by 23
Lee, M., Liu, K.-H., Thomas, J. L., Chen, J.-R., & Lin, H. (2019) · Biomolecules · doi:10.3390/biom9110651 · Cited by 21
“While PD-L1 expression allows cancer cells to evade immune surveillance by suppressing T-cell-mediated immunity [3], natural killer (NK) cells can also contribute to immunotherapy mediated by a PD-1/PD-L1 blockade; cancers with low major histocompatibility complex (MHC) expression are responsive to PD1 blockade via a…”
Gao, Y., Yang, C., He, N., Zhao, G., Wang, J., & Yang, Y. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.571545 · Cited by 21
“It has been reported that NK cells contribute to PD-1/PD-L1 antibody-mediated immunotherapy by expressing PD-L1 as a cytolytic effector (24, 25), while M2 macrophages help to generate an immune-evasive microenvironment in evolved cancers (26, 27).”
BackgroundBiomarkers for predicting the outcome of various cancer immunotherapies
Jafarzadeh, L., Khakpoor-Koosheh, M., Mirzaei, H., & Mirzaei, H. R. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103161 · Cited by 22
Metadata
- Authors
- Hsu, J., Hodgins, J. J., Marathe, M., Nicolai, C. J., Bourgeois-Daigneault, M.-C., Trevino, T. N., Azimi, C. S., Scheer, A. K., Randolph, H. E., Thompson, T. W., Zhang, L., Iannello, A., Mathur, N., Jardine, K. E., Kirn, G. A., Bell, J. C., McBurney, M. W., Raulet, D. H., & Ardolino, M.
- Affiliations
- University of California, Berkeley (US)
- University of Ottawa (CA)
- Corresponding author
- Raulet, David H.
- Ardolino, Michele
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2018-09-10
- Volume
- 128
- Issue
- 10
- Pages
- 4654-4668
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC6159991
- OpenAlex
- W2890056446
- Cited by
- 817
- References
- 82
- Citations by year
- 2026: 57 · 2025: 96 · 2024: 107 · 2023: 101 · 2022: 106 · 2021: 148 · 2020: 124 · 2019: 68 · 2018: 7
- FWCI
- 37.29
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- Canadian Institutes of Health Research
- National Cancer Institute (R01CA093678)
- National Institute of General Medical Sciences (T32GM007232)
- National Institute of Allergy and Infectious Diseases (R01AI113041)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- natural killer cells, PD-1, PD-L1, immune checkpoint blockade, cancer immunotherapy, NK cell exhaustion, antitumor immunity, NK cell activation, tumor immunosuppression, MHC expression
- MeSH terms
- Animals, Humans, Immunotherapy, Killer Cells, Natural, Neoplasms, Experimental, Mice, Knockout, K562 Cells, Mice, B7-H1 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.